Jazz Pharmaceuticals’ (JAZZ) “Buy” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $210.00 price objective on the specialty pharmaceutical company’s stock.

Several other equities analysts also recently issued reports on JAZZ. Barclays reiterated an “overweight” rating and set a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. JPMorgan Chase & Co. increased their price target on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. TD Cowen reduced their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Finally, Royal Bank of Canada reduced their target price on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $182.47.

Jazz Pharmaceuticals Stock Up 0.9 %

Shares of Jazz Pharmaceuticals stock opened at $140.23 on Wednesday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The firm has a market cap of $8.52 billion, a P/E ratio of 19.75, a P/E/G ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals has a fifty-two week low of $99.06 and a fifty-two week high of $148.06. The business has a 50-day moving average price of $127.64 and a 200 day moving average price of $119.71.

Insiders Place Their Bets

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the sale, the chief executive officer now directly owns 439,744 shares of the company’s stock, valued at approximately $53,785,088.64. This represents a 0.34 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Patricia Carr sold 4,813 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.42, for a total transaction of $695,093.46. Following the completion of the sale, the chief accounting officer now directly owns 8,237 shares in the company, valued at approximately $1,189,587.54. The trade was a 36.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,113 shares of company stock valued at $2,551,834 in the last three months. 4.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in JAZZ. IFP Advisors Inc bought a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth approximately $25,000. Quadrant Capital Group LLC raised its stake in shares of Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after acquiring an additional 101 shares during the last quarter. Elequin Capital LP increased its position in shares of Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock worth $26,000 after buying an additional 183 shares during the period. CoreFirst Bank & Trust acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth $28,000. Finally, Allianz SE acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth $29,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.